Abstract:Rationale: Up to 30% of COVID-19 patients experience persistent sequelae, including dyspnea, restrictive physiology, and early radiographic signs of pulmonary fibrosis (PF). The mechanisms that provoke post-COVID progressive PF are poorly understood, and biomarkers to identify at-risk patients are urgently needed. Methods: We evaluated a cohort of 14 symptomatic COVID survivors with impaired respiratory function and imaging worrisome for developing PF, including bilateral reticulation, traction bronchiectasis and/or honeycombing, and compared these to Idiopathic Pulmonary Fibrosis (IPF) patients and age-matched controls without respiratory disease. We performed single-cell RNA-sequencing and multiplex immunostaining on peripheral blood mononuclear cells collected at the COVID-19 patients’ first visit after ICU discharge. Six months later, symptoms, restriction and PF improved in some (Early-Resolving COVID PF), but persisted in others (Late-Resolving COVID PF). Results: Circulating monocytes were significantly reduced in Late-Resolving COVID PF patients compared to Early-Resolving COVID PF and non-diseased controls. Monocyte abundance correlated with pulmonary function tests FVC and DLCO. Differential expression analysis revealed MHC-II class molecules were upregulated on the CD8 T cells of Late-Resolving COVID PF patients but downregulated in monocytes. IPF patients had a similar decrease in monocyte abundance and marked decrease in monocyte HLA-DR protein expression compared to Late-Resolving COVID PF patients. Conclusion: Circulating monocyte abundance may distinguish between patients whose post-COVID PF resolves or persists. Furthermore, fibrotic progression coincided with decreases in HLA-DR expression on monocytes, a phenotype previously associated with dampened antigen stimulation and severe respiratory failure. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement The authors thank the UVA Genome Analysis and Technology Core for their technical expertise in single-cell RNA sequencing and the funding that supported this work: NHLBI 5K23HL143135-04, University of Virginia Engineering in Medicine Seed Fund, Global Infectious Diseases Institute COVID-19 Rapid Response (CAB), UVA Robert R. Wagner Fellowship (GCB), R21 AI160334 and U01 AI125056 (JAW). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: All studies performed at University of Virginia were given ethical approval by the University of Virginia Human Investigations Committee. Studies performed at the Mayo Clinic were approved by Mayo Clinic Institutional Review Boards (protocol ID 20-004911). All subjects provided written informed consent. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors. Please email corresponding authors for supplemental tables and figures.

Single cell sequencing reveals cellular landscape alterations in the airway mucosa of patients with pulmonary long COVID

Longitudinal Clinical and Radiographic Evaluation Reveals Interleukin-6 As an Indicator of Persistent Pulmonary Injury in COVID-19

Single-Cell RNA Sequencing Reveals Alterations in Patient Immune Cells with Pulmonary Long COVID-19 Complications

Identification of abnormal airway niches in the fibrotic lung using spatial transcriptomics

Single‐cell RNA sequencing reveals characteristics of myeloid cells in post-acute sequelae of SARS-CoV-2 patients with persistent respiratory symptoms

Multi-omics landscapes reveal heterogeneity in long COVID patients characterized with enhanced neutrophil activity

Single-cell analysis of bronchoalveolar cells in inflammatory and fibrotic post-COVID lung disease

The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing

Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease

Differential Gene Expression in the Upper Respiratory Tract following Acute COVID-19 Infection in Ambulatory Patients That Develop Long COVID

Longitudinal analysis of the lung proteome reveals persistent repair months after mild to moderate COVID-19

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

A single-cell transcriptomic landscape of the lungs of patients with COVID-19

Probing long COVID through a proteomic lens: a comprehensive two-year longitudinal cohort study of hospitalised survivors

Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2

Reduction in circulating monocytes correlates with persistent post-COVID pulmonary fibrosis in multi-omic comparison of long-haul COVID and IPF

Distinct Type 1 Immune Networks Underlie the Severity of Restrictive Lung Disease after COVID-19

Chronic lung inflammation and CK14+ basal cell proliferation induce persistent alveolar-bronchiolization in SARS-CoV-2-infected hamsters

Distinguishing features of Long COVID identified through immune profiling

Innate immune cell activation causes lung fibrosis in a humanized model of long COVID

Novel Insight into the Underlying Dysregulation Mechanisms of Immune Cell-to-cell Communication by Analyzing Multitissue Single-Cell Atlas of Two COVID-19 Patients